<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789813</url>
  </required_header>
  <id_info>
    <org_study_id>2016DR2001</org_study_id>
    <nct_id>NCT02789813</nct_id>
  </id_info>
  <brief_title>Influence of Valproic Acid on Extinction-based Therapy in Patients With Fear of Spiders.</brief_title>
  <acronym>VALPRO</acronym>
  <official_title>Randomized Placebo-controlled Phase II Study on the Influence of Valproic Acid in Combination With Reactivation of Fear Memory on the Outcome of Extinction-based Therapy in Patients With Fear of Spiders.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dominique de Quervain, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Basel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether valproic acid in combination with fear
      memory reactivation is useful to enhance treatment stability of exposure therapy for specific
      phobia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  There will be one screening visit (visit 1), one intervention visit (visit 2) and one
           follow-up visit (90 days after visit 2) (visit 3).

        -  On visit 2 all participants will undergo 30 min exposure therapy in virtual reality with
           pre-defined spider situations.

        -  Duration for an individual participant will be at most 15 weeks depending on the time
           passing between screening (visit 1) and intervention visit (visit 2).

        -  Change in phobic fear to baseline (visit 1) will be assessed on 90 day follow-up (visit
           3).

        -  Documentation of all study relevant source data of every study participant will be done
           by completing the study specific electronic case report forms (eCRF, SoSci Survey) and
           study specific case report forms on paper (Adverse Events, Serious Adverse Events and
           concomitant medication). Data in the eCRF can be validated for completeness and
           discrepancies automatically. An audit trail system maintains a record of initial entries
           and changes (reasons for changes, time and date of changes, user identification of entry
           and changes).

        -  Quality insurance will be done by an external site monitoring (including study progress,
           accuracy and completeness of eCRF, fulfillment of protocol requirements, applicable
           local authority regulations and investigator's obligations).

        -  Monitoring includes 100% of safety parameters, primary endpoints, informed consent
           documents and the Trial Master File on the Initiation Visit and on Close Out.

        -  Standard Operating Procedures to address study activities such as patient recruitment,
           informed consent, study interventions, data collection, data management, data analysis,
           and reporting for adverse events exist.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in performance in Behavioral Approach Test (BAT) in real-life (in vivo)</measure>
    <time_frame>Baseline (visit 1: 7-21 days before visit 2: intervention) and follow up (visit 3: 90 days after visit 2: intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in performance in BAT in virtual reality (in virtuo)</measure>
    <time_frame>Baseline (visit 1: 7-21 days before visit 2: intervention) and follow up (visit 3: 90 days after visit 2: intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective reactions in BAT in virtual reality (in virtuo)</measure>
    <time_frame>Baseline (visit 1: 7-21 days before visit 2: intervention) and follow up (visit 3: 90 days after visit 2: intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in psychophysiological reactions in BAT in virtual reality (in virtuo)</measure>
    <time_frame>Baseline (visit 1: 7-21 days before visit 2: intervention) and follow up (visit 3: 90 days after visit 2: intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective reactions to fear-related picture cue presentation quantified by visual analog scales (VAS) for valence, arousal and fear</measure>
    <time_frame>Baseline (visit 1: 7-21 days before visit 2: intervention) and follow up (visit 3: 90 days after visit 2: intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in psychophysiological reactions to fear-related picture cue presentation quantified by electrodermal activity (EDA), heart rate (HR), startle response</measure>
    <time_frame>Baseline (visit 1: 7-21 days before visit 2: intervention) and follow up (visit 3: 90 days after visit 2: intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance in working and recognition memory of pictures task</measure>
    <time_frame>Follow up (visit 3: 90 days after visit 2: intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valence, arousal, and mood ratings of pictures of working and recognition memory of pictures task</measure>
    <time_frame>Follow up (visit 3: 90 days after visit 2: intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in strength of phobic fear quantified by self-report questionnaires</measure>
    <time_frame>Baseline (7-21 days before visit 2: intervention), intervention (visit 2: 7-21 days after visit 1: baseline) and follow up (visit 3: 90 days after visit 2: intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mood and state-anxiety quantified by self-report questionnaires</measure>
    <time_frame>Baseline (7-21 days before visit 2: intervention), intervention (visit 2: 7-21 days after visit 1: baseline) and follow up (visit 3: 90 days after visit 2: intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in performance during exposure in virtuo quantified by eye tracking</measure>
    <time_frame>Intervention (visit 2: 7-21 days after visit 1: baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective reactions during exposure in virtuo quantified by subjective units of discomfort (SUD) ratings</measure>
    <time_frame>Intervention (visit 2: 7-21 days after visit 1: baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in psychophysiological reactions during exposure in virtuo quantified by EDA and HR</measure>
    <time_frame>Intervention (visit 2: 7-21 days after visit 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical relevance of phobic symptoms measured by Diagnostic Interview for Psychiatric Disorders (DIPS), section for specific phobia</measure>
    <time_frame>Baseline (visit 1: 7-21 days before visit 2: intervention) and follow up (visit 3: 90 days after visit 2: intervention)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Baseline (7-21 days before visit 2: intervention), intervention (visit 2: 7-21 days after visit 1: baseline) and follow up (visit 3: 90 days after visit 2: intervention)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Baseline (7-21 days before visit 2: intervention), intervention (visit 2: 7-21 days after visit 1: baseline) and follow up (visit 3: 90 days after visit 2: intervention)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>Baseline (7-21 days before visit 2: intervention), intervention (visit 2: 7-21 days after visit 1: baseline) and follow up (visit 3: 90 days after visit 2: intervention)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>VAS of headache, stomach pain, nausea, fatigue, dizziness, drowsiness muscle fatigue, and motivation.</measure>
    <time_frame>Baseline (7-21 days before visit 2: intervention), intervention (visit 2: 7-21 days after visit 1: baseline) and follow up (visit 3: 90 days after visit 2: intervention)</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Phobia, Specific</condition>
  <arm_group>
    <arm_group_label>Valproic Acid and fear reactivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive once a combination of 500mg Valproic Acid (oral solution) and fear reactivation before exposure therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproic Acid and no fear reactivation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive once 500mg Valproic Acid (oral solution) before exposure therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and fear reactivation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will receive once a combination of Placebo (oral solution) and fear reactivation before exposure therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and no fear reactivation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will receive once Placebo (oral solution) before exposure therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>Once oral administration of 500mg before exposure therapy.</description>
    <arm_group_label>Valproic Acid and fear reactivation</arm_group_label>
    <arm_group_label>Valproic Acid and no fear reactivation</arm_group_label>
    <other_name>OrfirilÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once oral administration of 500mg before exposure therapy.</description>
    <arm_group_label>Placebo and fear reactivation</arm_group_label>
    <arm_group_label>Placebo and no fear reactivation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Fear reactivation</intervention_name>
    <description>Fear reactivation before exposure therapy.</description>
    <arm_group_label>Valproic Acid and fear reactivation</arm_group_label>
    <arm_group_label>Placebo and fear reactivation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>No fear reactivation</intervention_name>
    <description>No fear reactivation before exposure therapy.</description>
    <arm_group_label>Valproic Acid and no fear reactivation</arm_group_label>
    <arm_group_label>Placebo and no fear reactivation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV diagnosis of specific phobia (animal type: spider)

          -  BAT score (at screening) between 1 and 7 points

          -  Physically healthy

          -  Normotensive (90/60-140/90 mmHg)

          -  Male or female

          -  Aged between 18 and 40 years

          -  Native or fluent German-speaking

          -  Females have to be on effective birth control

        Exclusion Criteria:

          -  Other axis I disorder except a further comorbid phobic disorder

          -  Concurrent psychotherapy or pharmacotherapy

          -  Previous exposure-based therapy for specific phobia

          -  Parallel participation in another study

          -  Body weight less than 50kg

          -  Long-term medication intake

          -  Substance abuse

          -  5 or more cigarettes a day and/or inability of being abstinent for at least 5 hours

          -  Pregnancy or breast-feeding

          -  Kinetosis

          -  History of coagulation disease

          -  History of gastrointestinal disease

          -  Laboratory exclusion criteria: clinically relevant deviation of laboratory values
             (blood count, blood chemistry, coagulation status, liver and pancreas enzymes,
             electrolytes) from normal range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique JF de Quervain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorothee Bentz, PhD</last_name>
    <phone>+41 61 325 59 28</phone>
    <email>dorothee.bentz@upkbs.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlo A Huber, MD</last_name>
    <phone>+41 61 325 51 11</phone>
    <email>carlo.huber@upkbs.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Psychiatric University Clinics, University Basel</name>
      <address>
        <city>Basel</city>
        <zip>4012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothee Bentz, PhD</last_name>
      <phone>+41 61 325 5102</phone>
      <email>dorothee.bentz@upkbs.ch</email>
    </contact>
    <contact_backup>
      <last_name>Carlo A Huber, MD</last_name>
      <phone>+41 61 325 51 11</phone>
      <email>carlo.huber@upkbs.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Basel</investigator_affiliation>
    <investigator_full_name>Prof. Dominique de Quervain, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

